Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIntegumen Regulatory News (SKIN)

Share Price Information for Integumen (SKIN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.84
Bid: 1.70
Ask: 1.85
Change: 0.09 (5.14%)
Spread: 0.15 (8.82%)
Open: 1.75
High: 1.84
Low: 1.84
Yest. Close: 1.75
SKIN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Integumen PLC - Exercise of Warrants (update)

Thu, 11th Jul 2019 10:38

RNS Number : 2403F
Integumen PLC
11 July 2019
 

 

AIM share code: SKIN

11 July 2019

 

Integumen PLC

 

("Integumen" or "Company")

 

Exercise of Warrants (update)

 

Further to the announcement headed "Exercise of Warrants" notified on 10 July 2019, the Company confirms that application has been made for the 803,572 ordinary shares referred to in that announcement to be admitted to trading on AIM, which is expected to be on or about 16 July 2019. These shares will rank pari passu with the ordinary shares of the Company in issue.

 

Integumen plc

Gerard Brandon, CEO

 

+44 (0) 7340 055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

 

Neil Baldwin/Vassil Kirtchev

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker

+44 (0) 20 3621 4120

 

About Integumen:

Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

 

The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOESFWSUFFUSEDW
Date   Source Headline
11th May 20202:05 pmRNSSecond Price Monitoring Extn
11th May 20202:00 pmRNSPrice Monitoring Extension
6th May 20204:41 pmRNSSecond Price Monitoring Extn
6th May 20204:36 pmRNSPrice Monitoring Extension
6th May 20207:00 amRNSDoubling of production of Modern Water reagent

Login to your account

Don't have an account? Click here to register.